STOCK TITAN

Imunon (IMNN) CEO Stacy Lindborg gets 1,803-share stock grant in lieu of salary

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc.’s President and CEO Stacy Lindborg received a grant of 1,803 shares of common stock on June 18, 2026 at $1.82 per share. The stock was granted in lieu of cash for a portion of base salary, so it is compensation rather than an open-market purchase. Following this grant, Lindborg directly holds 7,038 common shares. A separate entry shows 778 common shares held indirectly through a 401(k) plan, which reflects a holding record rather than a new transaction.

Positive

  • None.

Negative

  • None.

Insights

CEO received routine stock-based pay, not an open-market buy.

Stacy Lindborg, President and CEO of Imunon, Inc., received 1,803 shares of common stock at $1.82 per share as compensation in lieu of a portion of base salary. This is coded as a grant/award acquisition rather than a market transaction.

After the award, Lindborg directly holds 7,038 common shares, plus 778 shares held indirectly via a 401(k) plan as of the same date. Because this is salary replacement, not discretionary buying or selling, it is typically viewed as a routine compensation event with neutral signaling value for investors.

Insider Lindborg Stacy
Role President and CEO
Type Security Shares Price Value
Grant/Award Common Stock 1,803 $1.82 $3K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 7,038 shares (Direct, null); Common Stock — 778 shares (Indirect, By 401(k) Plan)
Footnotes (1)
  1. [object Object]
Stock grant shares 1,803 shares Common stock granted June 18, 2026
Grant price $1.82 per share Value used for stock granted in lieu of salary
Direct holdings after grant 7,038 shares Common stock directly held by CEO after transaction
Indirect 401(k) holdings 778 shares Common stock held indirectly via 401(k) plan
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
401(k) Plan financial
"nature_of_ownership: By 401(k) Plan"
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
indirect ownership financial
"ownership_type: indirect"
non-derivative financial
"transaction_type: non-derivative"
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lindborg Stacy

(Last)(First)(Middle)
C/O IMUNON, INC.
997 LENOX DRIVE, SUITE 100

(Street)
LAWRENCEVILLE NEW JERSEY 08648

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A1,803(1)A$1.827,038D
Common Stock778IBy 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Stock granted in lieu of cash for portion of base salary
/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Imunon (IMNN) CEO Stacy Lindborg report in this Form 4?

Stacy Lindborg reported receiving 1,803 shares of Imunon common stock as compensation. The shares were granted at $1.82 per share in lieu of a portion of base salary, increasing her directly held position to 7,038 shares as of the transaction date.

Was the Imunon (IMNN) CEO’s Form 4 an open-market stock purchase?

No, the Form 4 shows a stock grant, not an open-market purchase. Stacy Lindborg received 1,803 common shares at $1.82 per share as equity compensation in place of part of her cash salary, which is classified as a grant/award acquisition.

How many Imunon (IMNN) shares does CEO Stacy Lindborg hold after this grant?

After the June 18, 2026 grant, Stacy Lindborg directly holds 7,038 Imunon common shares. In addition, a separate holding entry lists 778 common shares held indirectly through a 401(k) plan, reflecting retirement-plan ownership associated with her position.

What price was used for the Imunon (IMNN) stock granted to the CEO?

The 1,803 Imunon common shares granted to CEO Stacy Lindborg were valued at $1.82 per share. This price is used to record the equity compensation that replaced a portion of her base salary, rather than representing an open-market trading price decision.

How should investors view this Imunon (IMNN) Form 4 transaction?

This Form 4 reflects routine equity compensation, not a discretionary trade. The 1,803 shares granted at $1.82 per share replaced part of Stacy Lindborg’s cash salary. Such grants typically carry neutral signaling value, mainly showing the company’s use of stock-based pay.